Rifabutin‐ and furazolidone‐based <scp>Helicobacter pylori</scp> eradication therapies after failure of standard first‐ and second‐line eradication attempts in dyspepsia patients

Abstract

Available H. pylori eradication therapies remain very effective and compliance to guidelines achieves high success rates. Furazolidone-based 'rescue' regimen achieved high eradication rates after failure of the standard first-line, second-line and rifabutin-based therapies.